Edition:
United Kingdom

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

5.15USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$5.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
12,680
52-wk High
$6.85
52-wk Low
$2.78

Latest Key Developments (Source: Significant Developments)

Proqr Q4 Loss Per Share ‍Eur 0.39
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Proqr Therapeutics Nv ::PROQR ANNOUNCES RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017 AND PROVIDES BUSINESS UPDATE.PROQR THERAPEUTICS NV - ‍CASH OF EUR 48.0 MILLION AT YEAR-END EXPECTED TO FUND OPERATIONS THROUGH ANTICIPATED CLINICAL DATA READOUTS IN 3 DIFFERENT PROGRAMS​.PROQR THERAPEUTICS NV QTRLY LOSS PER SHARE ‍ EUR 0.39.  Full Article

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Proqr reports loss of EUR 0.42 per share​
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Proqr Therapeutics Nv :Proqr announces results for the third quarter of 2017.Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​.  Full Article

ProQR Therapeutics prices public offering
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - ProQR Therapeutics Nv :ProQR prices approximately $20 million underwritten public offering and concurrent registered direct offering of ordinary shares.Pricing of offering of its ordinary shares at a price to public of $3.25 per share​.  Full Article

Proqr announces proposed public offering of ordinary shares
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Proqr Therapeutics Nv :Proqr announces proposed public offering of ordinary shares.Proqr - To use proceeds from both offerings to fund clinical trials, ongoing research & development activities​.  Full Article

ProQR doses first LCA 10 patient in clinical trial of QR-110
Monday, 13 Nov 2017 

Nov 13 (Reuters) - ProQR Therapeutics NV :ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness.ProQR Therapeutics - ‍interim safety and efficacy trial results for QR-110​ from majority of patients after 6 months of treatment are expected in 2018.ProQR Therapeutics - full 12 month treatment data for QR-110 from all patients are expected in 2019​.  Full Article

JDG B.V. reports 10.5 pct passive stake in ProQR Therapeutics NV as on Sept 14
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Proqr Therapeutics Nv :JDG B.V. Reports 10.5 percent passive stake in ProQR Therapeutics NV as on September 14 - SEC Filing‍​.  Full Article

ProQR announces positive top-line results from a phase 1b study of QR-010
Monday, 25 Sep 2017 

Sept 25 (Reuters) - ProQR Therapeutics NV :ProQR announces positive top-line results from a Phase 1b study of QR-010 in subjects with Cystic Fibrosis.ProQR Therapeutics - ‍QR-010 observed to be safe and well-tolerated across all doses in the trial with no serious adverse events related to treatment​.ProQR Therapeutics NV - Co, Cystic Fibrosis Foundation Therapeutics intend to expand their partnership to explore inhaled Oligonucleotide platform.  Full Article

ProQR gets orphan drug designation from FDA for drug candidate QR-313
Tuesday, 19 Sep 2017 

Sept 19 (Reuters) - ProQR Therapeutics NV :ProQR receives orphan drug designation from FDA for drug candidate QR-313 for dystrophic epidermolysis bullosa and will present data at two scientific conferences.ProQR Therapeutics NV - first-in-human clinical trial of QR-313 will be initiated in 2018.ProQR Therapeutics NV - clinical data from QR-313 program will also be available in 2018.  Full Article

ProQR Therapeutics spins out Amylon Therapeutics
Tuesday, 12 Sep 2017 

Sept 12 (Reuters) - ProQR Therapeutics Nv ::ProQR therapeutics - spun out Amylon Therapeutics, a privately-held company focused on development of therapies for central nervous system disorders.ProQR Therapeutics Nv - ‍as part of deal, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders​.ProQR Therapeutics - retains majority ownership in amylon, entitled to future milestones, royalties from products developed by Amylon.ProQR Therapeutics NV - Amylon will be led by Thomas De Vlaam as founding CEO.  Full Article

BRIEF-ProQR Announces Q1 Loss Per Share Eur 0.34

* AT MARCH 31, 2018, PROQR HELD CASH AND CASH EQUIVALENTS OF €38.0 MILLION, COMPARED TO €48.1 MILLION AT DECEMBER 31, 2017 Source text for Eikon: Further company coverage: